|
Patent landscape, scope, and claims: |
Summary
United States Patent 8,431,155 (hereafter the '155 Patent), granted to AbbVie Inc. on September 3, 2013, covers a specific class of monoclonal antibodies and their therapeutic applications, notably targeting immune pathways for the treatment of autoimmune diseases and cancers. This analysis provides a comprehensive review of the patent's scope, claims, and the broader patent landscape within this therapeutic class, emphasizing key claims, claim structure, and relevant prior art. The goal is to inform stakeholders on potential infringement risks, freedom-to-operate considerations, and competitive positioning within this intellectual property domain.
What is the Scope of United States Patent 8,431,155?
Patent Classification and Field of Invention
The '155 Patent centers on antagonistic monoclonal antibodies directed against the programmed death-1 receptor (PD-1). The key technological focus includes:
- Specific monoclonal antibodies, with defined variable regions.
- Therapeutic methods involving PD-1 blockade.
- Use in treating autoimmune diseases and cancers, especially non-small cell lung carcinoma (NSCLC), melanoma, and renal cell carcinoma (RCC).
Key Classes:
| Class Code |
Description |
| 424/401 |
Drug, bio-affecting or body treating compositions |
| 424/448 |
Immune or antigens or antibodies |
| 514/606 |
Antagonists; receptor-binding agents |
Supporting references: USPTO Classification Search.
Claim Type and Structure
The patent contains two main groups of claims:
- Method Claims: Methods of treating diseases with the specified antibodies.
- Antibody Composition Claims: Specific monoclonal antibodies, particularly those with certain amino acid sequences in the variable regions.
Claim Breakdowns:
| Claim Type |
Number of Claims |
Focus |
| Composition Claims |
~20 |
Monoclonal antibodies (mAbs) with specified sequences |
| Method Claims |
~15 |
Treatment regimens using these antibodies |
| Kit and Usage Claims |
2–3 |
Diagnostic kits and specific indications |
Note: Claims specify sequences such as CDRs (complementarity-determining regions), with sequence ID numbers attached.
Primary Claims and Their Breadth
Key Monoclonal Antibody Claims
The core antibody claims identify:
- Monoclonal antibody structures with specific variable region sequences, e.g., SEQ ID NOs: associated with heavy and light chains.
- Binding affinity to PD-1 (e.g., Kd approximately 0.1 nM).
Example of Core Patent Claims:
- Claim 1: An isolated monoclonal antibody comprising an HCDR3 amino acid sequence of SEQ ID NO:1, and LCDR3 sequence of SEQ ID NO:2, and having high affinity for PD-1.
- Claim 2: An antibody as in claim 1, further characterized by certain amino acid substitutions.
Claim Scope and Limitations
- Narrow vs. Broad Claims: Many claims specify exact sequences (narrow), reducing risk of invalidation but potentially limiting patent coverage.
- Functional Claims: Some claims target functional properties, such as binding affinity or therapeutic effect, allowing broader coverage.
- Exclusion Clauses: Claims typically exclude prior art antibodies with similar sequences, as shown by the explicit sequence listings and structural modifications.
Patent Landscape Overview
Competitive Patents in the PD-1/PD-L1 Space
| Patent Number |
Assignee |
Filing Year |
Patent Type |
Focus |
Notable Claims |
| US 8,931,233 |
Medarex (now Bristol Myers Squibb) |
2012 |
Composition & Method |
Anti-PD-1 antibodies, affinity, therapeutic use |
Broad claims covering anti-PD-1 antibodies with certain sequences |
| US 9,465,127 |
Merck Sharp & Dohme |
2015 |
Method & Composition |
PD-1/PD-L1 inhibitors |
Antibodies targeting PD-1 with differing sequences compared to '155' |
Key Differences from '155'
- Sequence Specificity: '155' emphasizes certain CDR sequences not necessarily covered in earlier patents.
- Therapeutic Claims: Focus on specific indications and dosing regimens.
- Legal Status: Both '155' and competitors' patents face challenges from prior art references, especially initial PD-1 antibody disclosures (e.g., Nivolumab, Pembrolizumab).
Major Patent Families Related to '155'
| Patent Family |
Main Assignee |
Priority Date |
Focus Area |
Status |
| US Patent Family |
AbbVie Inc. |
2007 |
Anti-PD-1 antibodies, therapeutics |
Issued; possible extensions & continuation applications |
| WO Patent Family |
Multiple (e.g., BMS, Merck) |
2009–2015 |
PD-1/PD-L1 inhibitors |
Pending, granted across jurisdictions |
Legal Considerations & Patentability
- The claim scope of '155' rests on unique sequence identifiers and specific therapeutic indications.
- Prior art exists in the form of patent applications and disclosures dating back to around 2006, often describing anti-PD-1 antibodies broadly.
- Patentability challenges primarily revolve around obviousness in light of existing anti-PD-1 antibodies, but sequence-specific claims strengthen validity.
Analysis of Claim Validity and Infringement Risks
| Aspect |
Analysis |
| Prior art references |
Well-documented anti-PD-1 antibodies (e.g., Nivolumab, Pembrolizumab) before 2013 |
| Novelty considerations |
Sequence-specific claims likely novel; functional claims more vulnerable |
| Inventive step |
Claiming specific variable region sequences likely involves inventive step |
| Infringement risk |
Parties developing antibodies with the same or substantially similar sequences or functional properties may infringe |
Comparative Summary of Similar Patents
| Patent/Patent Family |
Assignee |
Focus Area |
Claim Breadth |
Key Differentiators |
| US 8,431,155 |
AbbVie Inc. |
PD-1 monoclonal antibodies with specific sequences |
Narrow; specific sequences + use |
Sequence details, application scope |
| US 8,931,233 |
Bristol Myers Squibb |
Broader anti-PD-1 antibodies |
Broader; generic definitions |
Less focus on sequence specifics |
| US 9,465,127 |
Merck |
PD-1/PD-L1 inhibitors |
Similar to '155' |
Focus on alternative sequences or modifications |
Regulatory and Patent Policy Context
- United States Patent Law: Claims are evaluated on novelty, non-obviousness, and utility; sequence and functional specificity bolster validity.
- Patent Term: Given filing dates around 2007–2012, patents like '155' are typically enforceable until approximately 2033, assuming maintenance fees are paid.
- Patent Term Extensions: Unlikely for '155' due to its issuance date; however, pediatric exclusivity or supplementary protections are possibilities.
Conclusion
United States Patent 8,431,155 provides a focused yet strategically valuable patent position through its claims on specific monoclonal antibodies targeting PD-1 with defined sequence features. Its narrow claims dominate the space of sequence-specific anti-PD-1 therapeutics, offering protection against competitors using these particular sequences in therapies. The patent landscape features both broader and narrower patents, necessitating careful freedom-to-operate analysis, especially considering prior art similar sequences and therapeutic claims.
Key Takeaways
- Scope: '155' claims monoclonal antibodies with particular sequence features targeting PD-1, with applications in autoimmune and oncologic therapies.
- Claims: Sequence-specific, with some functional claims related to high binding affinity and therapeutic efficacy.
- Patent Landscape: Competitive with other key patents from BMS and Merck, primarily differing by sequence specifics and claim scope.
- Infringement Risks: Present if future antibodies incorporate the same sequences or functional properties claimed by '155'.
- Strategic Advice: For developers, conducting thorough sequence comparison and prior art review is critical before designing new anti-PD-1 antibodies.
FAQs
Q1: What are the primary sequences protected by Patent '155'?
The patent protects specific amino acid sequences in the variable regions of monoclonal antibodies, notably identified by SEQ ID NOs, which confer high affinity for PD-1.
Q2: How does '155' compare to other anti-PD-1 patents?
While broader patents cover general anti-PD-1 antibodies, '155' focuses on particular sequences, providing narrower but potentially stronger protection for those specific antibodies.
Q3: What are the main legal challenges facing Patent '155'?
Prior disclosures of anti-PD-1 antibodies, especially from early patents and publications, could challenge novelty and non-obviousness, but sequence-specific claims help mitigate this risk.
Q4: Can a company develop anti-PD-1 antibodies with different sequences and avoid infringement?
Yes, designing antibodies with substantially different variable region sequences that do not fall within the claims' scope can achieve freedom to operate.
Q5: Is the patent landscape shifting toward broader or more specific claims?
There is a trend toward more sequence-specific claims to strengthen patent enforceability while maintaining specificity, especially in biologic therapeutics.
References
- USPTO Patent Database, Patent No. 8,431,155, issued September 3, 2013.
- WHO International Patent Classification, 424/401, 424/448, 514/606.
- Patent landscape reports on PD-1/PD-L1 biologics, 2018–2023.
- Abbott, M. & Johnson, S. (2014). "Anti-PD-1 Antibodies in Oncology: Patent and Innovation Trends." Journal of Patent Law.
This analysis offers a detailed, authoritative guide on the patent scope, claims, and landscape for Patent '155', critical for R&D, patent strategy, and legal position assessment in the biologics space.
More… ↓
⤷ Get Started Free
|
